The estimated Net Worth of Jennifer Ling Lee is at least $361 Tisíc dollars as of 9 March 2020. Jennifer Lee owns over 361 units of Moderna Inc stock worth over $351,355 and over the last 8 years Jennifer sold MRNA stock worth over $9,866.
Jennifer has made over 6 trades of the Moderna Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Jennifer sold 361 units of MRNA stock worth $9,866 on 9 March 2020.
The largest trade Jennifer's ever made was exercising 4,019 units of Moderna Inc stock on 22 May 2017 worth over $319,551. On average, Jennifer trades about 1,139 units every 85 days since 2016. As of 9 March 2020 Jennifer still owns at least 4,419 units of Moderna Inc stock.
You can see the complete history of Jennifer Lee stock trades at the bottom of the page.
Jennifer's mailing address filed with the SEC is C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein a Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: